LEARNING OBJECTIVES

• Discuss the evolution of treatment in relapsed/refractory mantle cell lymphoma (MCL) with focus on new therapies
• Review optimal patient management strategies and best practice
• Understand the multidisciplinary roles in patient assessment and treatment

WEDNESDAY Oct 23, 2019

MUHC- GLEN
8:30 - 9:30
Room D02.1312

Hôpital Charles LeMoyne
12:00 – 13:00
Room HN-106
(lecture by videoconference from CHUS Sherbrooke)

WEDNESDAY Oct 23, 2019

CHUM
17:00 - 18:00
Room D.S4.5030
Live on the Web! www.vpsolution.tv/vspo
Problems/Questions: 514-813-4510

CHUS Sherbrooke (not a VSPO-affiliated lecture)
12:00 – 13:00
Room X5-7512

Refreshments will be served.
To organize a videoconference:
vsopo@mcgill.ca

This program has received an educational grant from:
AbbVie, Amgen, Apobiologix, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisai, Eli Lilly, Gilead, Janssen, Merck, Novartis, Pfizer, Roche, Seattle Genetics, Servier, Takeda, Teva Canada Innovation